Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oregovomab - OncoQuest

X
Drug Profile

Oregovomab - OncoQuest

Alternative Names: Anti-CA125-monoclonal-antibody-B43-13-AltaRex; Anti-idiotype-ovarian-cancer-vaccine-AltaRex; Anti-idiotype-ovarian-cancer-vaccine-CA125; Mab B43.13; Monoclonal antibody B43.13; OvaRex; Ovarian-cancer-vaccine-AltaRex

Latest Information Update: 19 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AltaRex
  • Developer National Cancer Centre (Singapore); National Cancer Institute (USA); OncoQuest; University of Nebraska Medical Center; Yonsei University
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Pancreatic cancer

Most Recent Events

  • 31 May 2024 Adverse events and efficacy data from a phase II FLORA-4 trial in Ovarian cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
  • 08 Aug 2023 CanariaBio completes enrolment in its phase II trial in Peritoneal cancer (Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (IV) (NCT05335993)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top